Last updated: Oct 15, 2026 · Built by a patient who got tired of scrolling ClinicalTrials.gov
Active interventional trials with status RECRUITING or NOT_YET_RECRUITING. A multi-phase trial (e.g. 1/2) is counted in each of its phases.
Biomarkers, stage, prior treatments — get a ranked shortlist in minutes.
Recruiting trials grouped by drug class. Trials with unclassifiable or non-therapeutic interventions are excluded from this view.
| NCT | Phase | Title | Mechanism |
|---|---|---|---|
| NCT07105176 | 1 | HS-IT101 Injection for Advanced NSCLC(FASTIL-Lung01) | Unknown mechanism |
| NCT04267848 | 3 | Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) | PD-1 -- immune checkpoint inhibitor (monoclonal antibody) |
| NCT07185997 | 3 | Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations | EGFR PACC uncommon mutations -- EGFR tyrosine kinase inhibitor (TKI) |
| NCT06931717 | 3 | A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy | PD-1 -- immune checkpoint inhibitor |
| NCT07462377 | 1 | A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC | Unknown mechanism |
| Sponsor | Recruiting trials |
|---|---|
| Sun Yat-sen University | 33 |
| Shanghai Pulmonary Hospital, Shanghai, China | 31 |
| Tianjin Medical University Cancer Institute and Hospital | 28 |
| Shanghai Chest Hospital | 22 |
| Fudan University | 21 |
Countries/regions with the most active trial sites for lung cancer (nsclc). A multi-site trial is counted once per country/region.
Phase-1 trials whose listed start date falls within the last 12 months — the leading edge of the field.
| Start | NCT | Title | Mechanism |
|---|---|---|---|
| Dec 1, 2027 | NCT05745740 | A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation | HER2 -- antibody-drug conjugate (ADC) + tyrosine kinase inhibitor (TKI) |
| Dec 1, 2026 | NCT06638125 | 3-Dimensional Virtual Reality Modelling With Intravascular Indocyanine Green Fluorescence Mapping for Targeted Pulmonary Segmental Resection Trial | Indocyanine green -- fluorescent dye for surgical navigation |
| Dec 2026 | NCT07594067 | TCR1188-ABC Cells in KRAS-mutated Cancers | KRAS mutant peptides -- T cell receptor (TCR) engineered T cells |
| Oct 30, 2026 | NCT07272642 | A Phase 1, Multicenter Imaging Study of LNTH-2403 in Participants With Locally Advanced or Metastatic Solid Tumors. | LRRC15 -- radiolabeled monoclonal antibody (radioimmunotherapy) |
| Oct 1, 2026 | NCT07842887 | Phase 1 Study of ATRA Plus a PD-1 Inhibitor in EGFR-Mutant NSCLC After Third-Generation EGFR-TKI Resistance | PD-1 -- immune checkpoint inhibitor (monoclonal antibody); Retinoic acid receptor -- differentiation inducer (small molecule) |
| Sep 28, 2026 | NCT07798921 | JIN-A02 Plus Amivantamab in EGFR-Mutant NSCLC After Third-Generation EGFR-TKI Failure | EGFR + MET -- bispecific antibody (Amivantamab) combined with unknown mechanism (JIN-A02) |
| Sep 21, 2026 | NCT07830342 | A Clinical Study of HS-IT101 Injection in Patients With Advanced Non-Small Cell Lung Cancer(FASTIL-Lung02) | Tumor-infiltrating lymphocytes (TILs) -- adoptive cell therapy |
| Sep 14, 2026 | NCT07619599 | A PET Imaging Agent (64Cu-DOTA-Pembrolizumab) for Determining Treatment Response Among Patients With Stage IV Non-small Cell Lung Cancer Receiving Pembrolizumab | PD-1 -- antibody (immune checkpoint inhibitor) |
You've seen the lung cancer (nsclc) landscape. Now find the trials that fit your case.
Enter biomarkers, stage, and prior treatments — get ranked matches with eligibility breakdown in minutes.
Find My Matches →Source: ClinicalTrials.gov, synced daily. Aggregated by ClinTrialFinder.